177 related articles for article (PubMed ID: 34021119)
41. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
42. Management of multiple myeloma in the relapsed/refractory patient.
Sonneveld P
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):508-517. PubMed ID: 29222299
[TBL] [Abstract][Full Text] [Related]
43. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Madduri D; Hagiwara M; Parikh K; Pelletier C; Delea TE; Kee A; Chari A
Future Oncol; 2021 Feb; 17(5):503-515. PubMed ID: 33522834
[No Abstract] [Full Text] [Related]
44. Proteasome inhibitors for the treatment of multiple myeloma.
Scalzulli E; Grammatico S; Vozella F; Petrucci MT
Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
[TBL] [Abstract][Full Text] [Related]
45. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
Fradley MG; Groarke JD; Laubach J; Alsina M; Lenihan DJ; Cornell RF; Maglio M; Shain KH; Richardson PG; Moslehi J
Br J Haematol; 2018 Jan; 180(2):271-275. PubMed ID: 29048105
[TBL] [Abstract][Full Text] [Related]
46. Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents.
Santoro M; Romano A; Mancuso S; Siragusa S; DI Raimondo F; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):1-6. PubMed ID: 32955183
[TBL] [Abstract][Full Text] [Related]
47. Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
Romano A; Santoro M; Conticello C; Siragusa S; DI Raimondo F; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):13-20. PubMed ID: 32955184
[TBL] [Abstract][Full Text] [Related]
48. Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
Piro E; Kropp M; Cantaffa R; Lamberti AG; Carillio G; Molica S
Ann Hematol; 2012 Nov; 91(11):1827-8. PubMed ID: 22584850
[No Abstract] [Full Text] [Related]
49. Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation.
Kint NG; Heylen E; Pepe D; De Keersmaecker K; Verfaillie CM; Delforge M
Leukemia; 2020 Feb; 34(2):651-655. PubMed ID: 31467428
[No Abstract] [Full Text] [Related]
50. Management of double-refractory multiple myeloma.
Meadows JP; Mark TM
Curr Hematol Malig Rep; 2013 Dec; 8(4):253-60. PubMed ID: 23975677
[TBL] [Abstract][Full Text] [Related]
51. [Treatment of multiple myeloma: renal function in relation to its prognosis].
Akashi M; Ohta M; Kitagawa S; Furukawa Y; Takeda K; Muroi K; Komatsu N; Ikeda K; Ohsaka A; Yoshida M
Rinsho Ketsueki; 1988 Nov; 29(11):1991-7. PubMed ID: 3236408
[No Abstract] [Full Text] [Related]
52. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Bilotti E
Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
[TBL] [Abstract][Full Text] [Related]
53. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis.
Minoia C; Pisapia G; Palazzo G; Ingrosso C; Buonanno M; Spinosa C; Prudenzano A; Pricolo G; Mazza P
Bone Marrow Transplant; 2015 Nov; 50(11):1486. PubMed ID: 26281030
[No Abstract] [Full Text] [Related]
54. Chemotherapy of myeloma: drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma.
Bergsagel DE
Hematol Oncol; 1988; 6(2):159-66. PubMed ID: 3292373
[No Abstract] [Full Text] [Related]
55. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
Vandross A
Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899
[TBL] [Abstract][Full Text] [Related]
56. Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
Patel VG; Cornell RF
Curr Oncol Rep; 2019 Mar; 21(4):29. PubMed ID: 30834998
[TBL] [Abstract][Full Text] [Related]
57. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
Bai Y; Su X
Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949
[TBL] [Abstract][Full Text] [Related]
58. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
59. Old and new generation proteasome inhibitors in multiple myeloma.
Montefusco V; Mussetti A; Salas MQ; Martinelli G; Cerchione C
Panminerva Med; 2020 Dec; 62(4):193-206. PubMed ID: 32957744
[TBL] [Abstract][Full Text] [Related]
60. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
Podar K; Pecherstorfer M
Expert Opin Pharmacother; 2017 Aug; 18(11):1061-1079. PubMed ID: 28604120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
